MedEquity Capital

MedEquity Capital is a private equity firm located in Wellesley Hills, Massachusetts, focusing on investments in small and lower middle market healthcare businesses. The firm manages a buyout fund that primarily targets healthcare services and life sciences companies across the United States. MedEquity Capital aims to leverage its expertise to support the growth and development of its portfolio companies in the healthcare sector.

Tom Beausejour

Principal

Leland Garrahan

Vice President

W. Brandon Ingersoll

Partner

Jeffrey T. Ward

Partner

7 past transactions

Qler Solutions

Series B in 2021
qler Solutions LLC develops an on-demand solution for the delivery of psychiatric care to patients in various care settings that include emergency departments, med-surg floors, behavioral in-patients, clinics, nursing homes, and more in the United States. The company was incorporated in 2016 and is based in Reston, Virginia.

LiceGuard

Acquisition in 2012
LiceGuard is a company focused on the treatment and prevention of lice through the development of non-toxic and pesticide-free products. Its offerings are designed to detect and eliminate lice effectively without the use of harmful chemicals, providing a natural solution for individuals dealing with lice infestations. By prioritizing safety and efficacy, LiceGuard aims to address lice problems in a way that is both effective and gentle on users.

OnCURE Medical

Debt Financing in 2003
Oncure was founded in 1998 and is dedicated to helping patients fight cancer through the delivery of extraordinary care. In addition, Oncure offers patients access to many of the most advanced technologies in radiation treatment. See Treatment Options for more information. Oncure does not own nor manage physician practices, rather it collaborates with its affiliated radiation oncologists to provide quality patient treatment. See Medical Advisory Board for details.

Decision Management International

Venture Round in 2001
Decision Management International, Inc. (DMI) is a leading provider of software products and consulting services for companies in FDA-regulated industries. They are internationally recognized for the development of paperless solutions for cGMP manufacturing operations that greatly reduce operational complexities and costs. These efficiencies have proven advantageous for heavily regulated companies that require detailed documentation and compliance reporting to various governmental agencies. DMI's fully integrated software product suite addresses documentation compliance procedures in the pharmaceutical, biotechnology, medical device and similar industries. DMI was established in 1993 as a consulting firm for pharmaceutical and related industries. Since its founding, DMI has developed successful complexity reduction software that leverages the Company's domain expertise. The Company, a Microsoft Certified Partner, initially created a document authoring solution and subsequently developed a technically innovative product suite that integrates document authoring, archiving, and electronic batch record solutions software for clients throughout the U.S., Canada and Europe. The Company's solid consulting track record and superior software applications have resulted in ongoing and repeat business engagements with its existing clients. In addition, DMI continues to attract an impressive roster of new clients.

VelQuest

Private Equity Round in 2000
VelQuest Corporation is the global leader in lab execution and instrument data capture software for pharmaceutical and medical device manufacturers. VelQuest solutions for lab information management, lab execution, batch record execution, and electronic data capture replace manual paper-based documentation processes, helping manufacturers to improve efficiency and reduce GMP compliance risks in quality and manufacturing operations.

TransMedics

Series A in 2000
TransMedics Group, Inc. is a medical technology company focused on enhancing organ transplant therapies for patients with end-stage organ failure. Headquartered in Andover, Massachusetts, the company has developed the Organ Care System (OCS), a portable technology that maintains donor organs in a near-physiological state during transport. The OCS includes specialized systems for various organs, such as OCS LUNG, which preserves and optimizes lungs; OCS Heart, designed to keep donor hearts metabolically active; and OCS Liver, currently under clinical evaluation for liver transplants. This innovative approach aims to reduce ischemia, improve organ viability, and potentially increase the availability of transplants, addressing critical needs in the field of organ transplantation. TransMedics was founded in 1998 and has positioned itself at the forefront of advancing organ preservation technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.